LDC4297 | CAS#1453834-21-3 | CDK7 inhibitor

MedKoo Cat#: 407486 | Name: LDC4297

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LDC4297, also known as LCD044297, is a potent and selective CDK7 inhibitor. LDC4297 exerts broad-spectrum antiviral activity. LDC4297 inhibits CDK7 in vitro in the nano-picomolar range. CDK7 inhibitor LDC4297 is a promising candidate for further antiviral drug development, possibly offering new options for a comprehensive approach to antiviral therapy.

Chemical Structure

LDC4297

CAS#1453834-21-3

Theoretical Analysis

MedKoo Cat#: 407486

Name: LDC4297

CAS#: 1453834-21-3

Chemical Formula: C23H28N8O

Exact Mass: 432.2386

Molecular Weight: 432.53

Elemental Analysis: C, 63.87; H, 6.53; N, 25.91; O, 3.70

Price and Availability

Size	Price	Availability
10mg	USD 200.00	2 Weeks
25mg	USD 400.00	2 Weeks
50mg	USD 650.00	2 Weeks
100mg	USD 1,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

LDC4297; LDC-4297; LDC 4297; LCD044297; LCD-044297; LCD 044297.

IUPAC/Chemical Name

N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

InChi Key

LSGRZENCFIIHNV-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H28N8O/c1-16(2)19-15-27-31-21(19)28-23(32-18-8-5-10-24-14-18)29-22(31)25-13-17-7-3-4-9-20(17)30-12-6-11-26-30/h3-4,6-7,9,11-12,15-16,18,24H,5,8,10,13-14H2,1-2H3,(H,25,28,29)

SMILES Code

CC(C)C(C=NN12)=C1N=C(OC3CNCCC3)N=C2NCC4=CC=CC=C4N5N=CC=C5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

LDC4297 is a selective inhibitor of CDK7 with an IC50 value of 0.13 nM.

In vitro activity:

This study provides first evidence for the antiviral potential of the CDK7 inhibitor LDC4297, i.e., in exerting a block of the replication of human cytomegalovirus (HCMV) in primary human fibroblasts at nanomolar concentrations (50% effective concentration, 24.5 ± 1.3 nM). As a unique feature compared to approved antiherpesviral drugs, inhibition occurred already at the immediate-early level of HCMV gene expression. Reference: Antimicrob Agents Chemother. 2015 Apr;59(4):2062-71. https://pubmed.ncbi.nlm.nih.gov/25624324/

In vivo activity:

This study presents first data for the in vivo efficacy of both experimental drugs (including LDC4297) using an established cytomegalovirus animal model (murine CMV replication in immunodefective Rag -/- mice). The main findings of this study are (i) a strong inhibitory potency against beta- and gamma-herpesviruses of both compounds in vitro, (ii) even more important, a pronounced anticytomegaloviral activity also exerted in vivo, that resulted from (iii) a restriction of viral replication to the site of infection, thus preventing organ dissemination, (iv) in the absence of major compound-associated adverse events. Reference: Antiviral Res. 2019 Jan;161:63-69. https://pubmed.ncbi.nlm.nih.gov/30452929/

	Solvent	mg/mL	mM
Solubility
	DMF	20.0	46.24
	DMSO	40.0	92.48
	Ethanol	20.0	46.24

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 432.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kolloch L, Kreinest T, Meisterernst M, Oeckinghaus A. Control of Expression of Key Cell Cycle Enzymes Drives Cell Line-Specific Functions of CDK7 in Human PDAC Cells. Int J Mol Sci. 2022 Jan 12;23(2):812. doi: 10.3390/ijms23020812. PMID: 35054996; PMCID: PMC8775745. 2. Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeitträger I, Bahsi H, Wagner S, Zischinsky G, Wolf A, Degenhart C, Unger A, Baumann M, Klebl B, Marschall M. A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrob Agents Chemother. 2015 Apr;59(4):2062-71. doi: 10.1128/AAC.04534-14. Epub 2015 Jan 26. PMID: 25624324; PMCID: PMC4356785. 3. Sonntag E, Hahn F, Bertzbach LD, Seyler L, Wangen C, Müller R, Tannig P, Grau B, Baumann M, Zent E, Zischinsky G, Eickhoff J, Kaufer BB, Bäuerle T, Tsogoeva SB, Marschall M. In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model. Antiviral Res. 2019 Jan;161:63-69. doi: 10.1016/j.antiviral.2018.11.008. Epub 2018 Nov 17. PMID: 30452929. 4. Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, Klebl B, Meisterernst M. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol. 2014 Oct 1;34(19):3675-88. doi: 10.1128/MCB.00595-14. Epub 2014 Jul 21. PMID: 25047832; PMCID: PMC4187722.

In vitro protocol:

In vivo protocol:

1. Sonntag E, Hahn F, Bertzbach LD, Seyler L, Wangen C, Müller R, Tannig P, Grau B, Baumann M, Zent E, Zischinsky G, Eickhoff J, Kaufer BB, Bäuerle T, Tsogoeva SB, Marschall M. In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model. Antiviral Res. 2019 Jan;161:63-69. doi: 10.1016/j.antiviral.2018.11.008. Epub 2018 Nov 17. PMID: 30452929. 2. Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, Klebl B, Meisterernst M. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol. 2014 Oct 1;34(19):3675-88. doi: 10.1128/MCB.00595-14. Epub 2014 Jul 21. PMID: 25047832; PMCID: PMC4187722.

1: Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeitträger I, Bahsi H, Wagner S, Zischinsky G, Wolf A, Degenhart C, Unger A, Baumann M, Klebl B, Marschall M. A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrob Agents Chemother. 2015 Apr;59(4):2062-71. doi: 10.1128/AAC.04534-14. Epub 2015 Jan 26. PubMed PMID: 25624324; PubMed Central PMCID: PMC4356785. 2: Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, Klebl B, Meisterernst M. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol. 2014 Oct 1;34(19):3675-88. doi: 10.1128/MCB.00595-14. Epub 2014 Jul 21. PubMed PMID: 25047832; PubMed Central PMCID: PMC4187722.